• Explore /
  • Poster
  • / Response rate to lenalidomide plus rituximab (R<sup>2</sup>) as independent of number of prior lines of therapy: Interim analysis of initial phase of MAGNIFY phase IIIb study of R<sup>2</sup> followed by maintenance in relapsed/refractory indolent NHL.

Response rate to lenalidomide plus rituximab (R2) as independent of number of prior lines of therapy: Interim analysis of initial phase of MAGNIFY phase IIIb study of R2 followed by maintenance in relapsed/refractory indolent NHL.

Abstract Poster

Authors

null

David Andorsky

Rocky Mountain Cancer Centers, US Oncology Research, Boulder, CO

David Andorsky , Morton Coleman , Abdulraheem Yacoub , Jason M. Melear , Heather Dawn Brooks , Suzanne R. Fanning , Kathryn S. Kolibaba , Frederick Lansigan , Chris Reynolds , Jiahui Li , Dongfang Liu , Mary Llorente , Justin L. Ricker , Jeff Porter Sharman

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Track

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Sub Track

Non-Hodgkin Lymphoma

Clinical Trial Registration Number

NCT01996865

Citation

J Clin Oncol 36, 2018 (suppl; abstr 7516)

DOI

10.1200/JCO.2018.36.15_suppl.7516

Abstract #

7516

Poster Bd #

153

Abstract Disclosures

Similar Posters

First Author: Umberto Vitolo

First Author: Loretta J. Nastoupil

First Author: Connie Lee Batlevi

First Author: Laurie Helen Sehn